Study 301: No OS or PFS Improvement With Eribulin vs Capecitabine in Previously Treated Locally Advanced or Metastatic Breast Cancer

Capsule Summary - Although OS, PFS, and ORR were similar after treatment with eribulin or capecitabine in women with pretreated locally advanced or metastatic breast cancer from Study 301, those with triple-negative, ER-negative, or HER2-negative tumors may benefit more from eribulin.
Source: Clinical Care Options Oncology - Breast Cancer - Category: Cancer & Oncology Source Type: research